RxDoctor Payments Data

Ernesto Salas, MD

Internal Medicine · Temecula, CANPI 1841380565

Payments from drug & device makers

$3,640in general payments, 2019–2025

Across 120 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$926
  • AstraZeneca$855
  • Amgen$492
  • Novo Nordisk$286
  • Lilly USA, LLC$253
  • Sanofi-aventis U.S. LLC$152
  • plus $676 from 14 others

What the payments were for

  • Food & beverage$3,629100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,640 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$48,960
Medicare patients
92
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$30,348
OzempicSemaglutide24$23,605
XareltoRivaroxaban33$21,083
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,377
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,312
Atorvastatin Calcium174$1,481
Losartan Potassium140$865
Levothyroxine Sodium64$743
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide50$736
Simvastatin75$662
Famotidine28$662
Gabapentin27$653
Folic Acid62$560
Amlodipine Besylate112$495
Metformin Hcl98$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$98$30,34834 claims
Novo NordiskOzempic$286$23,60524 claims
Johnson & JohnsonXarelto$926$21,08333 claims
GSKAnoro Ellipta$86$8,37714 claims
AstraZenecaBevespi Aerosphere$855$5,31212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →